Adalimumab/etanercept/infliximab

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2012年 / 1432卷 / 1期
关键词：
D O I：
10.1007/s40278-012-0154-6
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [1] Adalimumab/etanercept/infliximab
    Reactions Weekly, 2012, 1432 (1) : 6 - 6
  • [2] Switching of infliximab to either etanercept or adalimumab - The Cannock experience
    Roskell, S
    Barber, J
    Venkatachalam, S
    Mulherin, D
    Sheeran, TP
    Price, T
    RHEUMATOLOGY, 2005, 44 : I157 - I157
  • [3] A COMPARISON OF DRUG SURVIVAL TIMES FOR INFLIXIMAB, ADALIMUMAB AND ETANERCEPT
    Pocock, Joanna M.
    Albreshni, Samir
    Slack, Ruth
    Polydoropoulou, Varvara
    O'Reilly, David
    Oestoer, Andrew J.
    RHEUMATOLOGY, 2009, 48 : I69 - I69
  • [4] Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab
    Puxeddu, Ilaria
    Giori, Lucia
    Rocchi, Valeria
    Bazzichi, Laura
    Bombardieri, Stefano
    Tavoni, Antonio
    Migliorini, Paola
    Del Corso, Isabella
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 108 (02) : 123 - 124
  • [5] Adalimumab/etanercept/infliximabBronchospasm (first report with etanercept and infliximab): 5 case reports
    Reactions Weekly, 2006, 1110 (1) : 4 - 4
  • [6] Adalimumab/etanercept/infliximabGlomerulonephritis (first report for adalimumab and infliximab): 5 case reports
    Reactions Weekly, 2005, 1075 (1) : 6 - 6
  • [7] Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice
    Escudero-Vilaplana, Vicente
    Ramirez-Herraiz, Esther
    Alanon-Plaza, Estefania
    Trovato-Lopez, Nicolas
    Garcia-Vicuna, Rosario
    Carreno-Perez, Luis
    Morell-Baladron, Alberto
    Sanjurjo-Saez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (05) : 808 - 814
  • [8] Differential TNF-neutralizing potencies of adalimumab, etanercept, and infliximab
    Kaymakcalan, Z.
    Kalghatgi, L.
    Xiong, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 458 - 458
  • [9] Effect of certolizurnab pegol, etanercept, adalimumab and infliximab on cytokine production
    Brown, D.
    Nesbitt, A.
    Fossati, G.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 656 - 656
  • [10] A Risk-Benefit Assessment of Adalimumab, Etanercept, and Infliximab in Psoriasis
    Strober, B.
    Langley, R.
    Rozzo, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S16 - S16
12345